OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia

ANSTO is the leader in nuclear science in Australia and has extensive experience in the manufacturing of radiopharmaceutical diagnostics, therapies and medical devices, they are the perfect partner for OncoBeta to work with to introduce the Rhenium-SCT® product to Australia. Together, the parties will achieve a key milestone, bringing the production of Rhenium-SCT® closer to Australians suffering of non-melanoma skin cancer. OncoBeta is currently in the process of securing Australian Market Approval for its product.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Non-melanoma skin cancer is the most common type of cancer in Australia with over 500,000 people each year being diagnosed with one or more of these cancers.

ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, “ANSTO is proud to partner with OncoBeta to establish local manufacturing of Rhenium-SCT® and to continue delivering on our core mission of improving the health of Australians and supporting industry. ANSTO has a long-standing relationship with OncoBeta and look foward Australian patients having access to their innovative therapy for non-melanoma skin cancers. OncoBeta will join our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry.” 

Nicholas H. Vetter, Chief Operating Officer of OncoBeta® GmbH stated: “We are incredibly excited to start extending our production footprint to Australia. It’s a great pleasure to work towards solidifying a partnership with ANSTO so we can do our jobs: to bring the Rhenium-SCT® to large patient populations suffering of non-melanoma skin cancer. With this partnership we can finally move beyond trying to service the market from our other production sites in Europe or South Africa. It’s a perfect time to expand our business."

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About ANSTO

ANSTO leverages great science to deliver big outcomes. We partner with a broad range of industry partners to apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment.  ANSTO is the home of Australia’s most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.

For more information visit www.ansto.gov.au

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center gate near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

About gate – Garchinger Technologie- und Gründerzentrum

As a business incubator the gate is the first place to go to for high-tech-startups and is located on the research campus in Garching/Munich. More than 50 resident gate startups mainly appreciate the flexibly expandable offices in direct neigbourhood to the Technical University of Munich. In order to become mature entrepreneurs, the founders seek the local coach’s advice and can resort to a network of research and specialists.

Founders who have innovative ideas, especially within the range of CleanTech, Artificial Intelligence, Industry 4.0, MedTech, IT, Virtual & Augmented Reality or Robotics, meet passionate like-minded people at the gate.

Since it’s foundation in 2002, gate has supported more than 300 companies. This total package, subsidised by the Bavarian government, makes it „the gate to success for high-tech-startups“.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.